Vmbook Online ordering

Brainstorm Cell Therapeutics I

Brainstorm Cell Therapeutics Inc. (BCLI) is a public company that specializes in developing cellular therapies for neurodegenerative disorders. The company is headquartered in New York, USA and its stock is listed on the Nasdaq Capital Market.

Brainstorm Cell Therapeutics is focused on the development and commercialization of its NurOwn® technology, a proprietary autologous cellular therapy that uses stem cells taken from the patient's own bone marrow to produce and secrete neurotrophic factors, which are believed to support the survival and growth of damaged nerve cells.

The company is currently conducting a Phase 3 clinical trial of NurOwn® for the treatment of amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disorder. Additionally, Brainstorm Cell Therapeutics has also initiated a Phase 2 clinical trial of NurOwn® for the treatment of multiple sclerosis (MS), another neurodegenerative disorder.

As a public company, Brainstorm Cell Therapeutics is required to file financial reports and other disclosures with the Securities and Exchange Commission (SEC). Investors can access these documents, including financial statements and regulatory filings, on the SEC's website.

It's important to note that investing in the stock market always carries risks, including the loss of principal. Potential investors should carefully consider their own investment objectives, financial situation, and risk tolerance before investing in any security. They should also consult with a licensed financial professional or advisor before making any investment decisions.